IgA anti-β2 glycoprotein I antibodies: Experience from a large center

Vlagea, Alexandru; Pascual‐Salcedo, Dora; Doforno, Rita Álvarez; Lavilla, P; Díez, Jesús; Merlano, Beatriz Padilla; Cuesta, M V; Gil, Antonio

doi:10.1016/j.thromres.2017.12.007

Cited by 19 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the recent study, whether it is clinical manifestation criteria, mainly including arterial or venous thrombosis and pregnancy morbidity, or some other “non-criteria” clinical manifestations such as stroke and thrombocytopenia, there is no correlation between IgA–aPL positivity and clinical manifestations. In line with the previously published large cohort studies of APS patients, the results showed no association between IgA–aβ 2 GPI and APS manifestations in APS patients ( 18 , 19 ). Of note, whether in a laboratory or clinical setting, the detection of IgA–aPL does not provide more value for the diagnosis of APS as it can be replaced by IgG–aPL detection.…”

Section: Discussionsupporting

confidence: 91%

“…aPL is a critical laboratory biomarker for the diagnosis of APS. IgA–aPL, also known as a “non-criteria” aPL, has been shown to have a controversial diagnosis performance for APS in previous studies ( 19 , 20 , 25 ) and a systematic review ( 26 ). To the best of our knowledge, this is the first study to analyze the aPL profile based on 7,293 consecutive subjects from a large cohort in the general Chinese population.…”

Section: Discussionmentioning

confidence: 99%

“…However, whether IgA–aPL has the potential to become one of the diagnostic criteria is controversial. For instance, researchers have shown no association between IgA–aPL and clinical manifestations of APS ( 18 , 19 ). In addition, the detection of IgA–aPL does not increase the diagnostic sensitivity of APS ( 20 ) or help diagnose patients with APS-associated SLE ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population

Wang

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Objective Antiphospholipid syndrome (APS) is characterized by the presence of anti-phospholipid (aPL) antibodies. However, the relationship between the immunoglobulin (Ig) A isotype of aPL positivity and its clinical utility in APS diagnosis is controversial. Presently, we determine the clinical utility of IgA–aPL from consecutive patients in a large cohort from the Chinese population and patients with APS whose aPL profiles were obtained. Methods The detection of anticardiolipin (aCL) and anti-β 2 glycoprotein-Ⅰ (aβ 2 GPⅠ) antibodies of the IgA/IgG/IgM isotype by paramagnetic particle chemiluminescent immunoassay was carried out in sera from 7293 subjects. 153 primary APS (PAPS) patients and 59 patients with secondary APS (SAPS) were included in this study. Results In total, 1,082 out of 7,293 (2.55%) subjects had a positive IgA–aPL test, and the prevalence of isolated IgA–aPL was 0.29% (21/7,293) in the general population. The prevalence of IgA–aPL in the PAPS patients was 12.42% (19/153); however, only one patient (0.65%) presented with isolated IgA–aPL. Fifty (25.9%) of the SAPS had IgA–aPL, none of whom lacked IgG/IgM–aPL. The combination of the IgA isotype and the IgG/IgM isotype did not increase the diagnostic performance when compared with the IgG/IgM isotype of aCL or aβ 2 GPⅠ, respectively. IgA–aPL was not associated with clinical manifestation in patients with APS. Conclusion Isolated IgA–aPL is rare in the general population as well as in patients with APS. Whether in the laboratory or in clinical practice, the presence of IgA–aPL does not provide added value for the diagnosis of APS in the Chinese population.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population

Wang

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…APA can also interact with many different cell types through cell surface receptors, including TLR2, TLR4 and apolipoprotein E receptor 2 and so on. Their effects are mediated by the phosphatidylinositol 3‐kinase‐ras‐related C3 botulinum toxin substrate serine/threonine protein kinase pathway – mTOR or P38 mitogen‐activated protein kinase (p38MAPK) …”

Section: Antiphospholipid Antibodiesmentioning

confidence: 98%

“…The frequency of aPC was significantly high among women with unexplained infertility, recurrent implantation failure and recurrent pregnancy loss in the IgM isotype . However, there are studies that clearly show that there is no clear correlation between IgA‐type β2GPI and APA, and therefore IgA‐type β2GPI is not supported as a classification criterion for APA …”

Section: Antiphospholipid Antibodiesmentioning

confidence: 99%

Antibodies: The major participants in maternal–fetal interaction

Yang

Zhang

Chen

et al. 2018

J of Obstet and Gynaecol

View full text Add to dashboard Cite

The aim of this study is to improve our understanding of the mechanisms involved in maternal-fetal immune tolerance. We searched the related literatures and overviewed the major antibodies associated with pregnancy and described in details their possible roles in mediating maternal-fetal interactions. Antibodies classified into different types based on their functional or structural characteristics were summarized, including immunoglobulin G, blocking antibody, nonprecipitating asymmetric antibody, antiphospholipid antibody, antitrophoblast antibody and antipaternal antibody. The presence and levels of various circulating antibodies in pregnancy may play a crucial role in the occurrence, development and termination of pregnancy.

show abstract

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

Barbhaiya

Zuily

Ahmadzadeh

et al. 2021

Arthritis Care & Research

View full text Add to dashboard Cite

Objective An international multidisciplinary initiative, jointly supported by the American College of Rheumatology and European Alliance of Associations for Rheumatology, is underway to develop new rigorous classification criteria to identify patients with high likelihood of antiphospholipid syndrome (APS) for research purposes. The present study was undertaken to apply an evidence‐ and consensus‐based approach to identify candidate criteria and develop a hierarchical organization of criteria within domains. Methods During phase I, the APS classification criteria steering committee used systematic literature reviews and surveys of international APS physician scientists to generate a comprehensive list of items related to APS. In phase II, we reviewed the literature, administered surveys, formed domain subcommittees, and used Delphi exercises and nominal group technique to reduce potential APS candidate criteria. Candidate criteria were hierarchically organized into clinical and laboratory domains. Results Phase I generated 152 candidate criteria, expanded to 261 items with the addition of subgroups and candidate criteria with potential negative weights. Using iterative item reduction techniques in phase II, we initially reduced these items to 64 potential candidate criteria organized into 10 clinical and laboratory domains. Subsequent item reduction methods resulted in 27 candidate criteria, hierarchically organized into 6 additive domains (laboratory, macrovascular, microvascular, obstetric, cardiac, and hematologic) for APS classification. Conclusion Using data‐ and consensus‐driven methodology, we identified 27 APS candidate criteria in 6 clinical or laboratory domains. In the next phase, the proposed candidate criteria will be used for real‐world case collection and further refined, organized, and weighted to determine an aggregate score and threshold for APS classification.

show abstract

IgA anti-β2 glycoprotein I antibodies: Experience from a large center

Cited by 19 publications

References 31 publications

Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population

Immunoglobulin A Isotype of Antiphospholipid Antibodies Does Not Provide Added Value for the Diagnosis of Antiphospholipid Syndrome in a Chinese Population

Antibodies: The major participants in maternal–fetal interaction

Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

Contact Info

Product

Resources

About